Bristol Myers posts long-term Phase 3 data for schizophrenia drug Cobenfy
Bristol Myers Squibb's (BMY) new schizophrenia drug, Cobenfy, improves symptoms with a well-tolerated safety profile in two ...
Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious
Bristol Myers Squibb's revenue was fueled by Growth Portfolio and Eliquis. Analysts anticipate an impact from Cobenfy and a ...
Bristol Myers Squibb Boosts 2024 Outlook On Strong Demand For Blood Thinner Med, New Drugs Drive Q3 Profit
Bristol Myers Squibb Q3 revenue rose 8% YoY to $11.89 billion, driven by strong Growth Portfolio sales, especially Eliquis.
Bristol Myers earnings beat expectations, driven by sales of older drugs
Bristol Myers Squibb reported a higher-than-expected third-quarter profit on Thursday, citing strong sales of established ...
Bristol Myers’s stock pops as earnings top estimates and company raises guidance
Bristol-Myers Squibb Co.’s stock rose 2.9% early Thursday, after the drug company posted better-than-expected third-quarter earnings and raised its guidance. Princeton, N.J.-based Bristol Myers had ...
Bristol-Myers raises outlook ahead of consensus after Q3 beat
Bristol-Myers Squibb (BMY) stock gained as the comany exceeded Q3 2024 financial forecasts, with strong revenue growth and ...
NBC Los Angeles5d
Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs
Bristol Myers Squibb reported third-quarter earnings and revenue that blew past expectations on strong sales from its blood thinner Eliquis and a portfolio of drugs it expects to deliver long-term ...